Sept 11 (Reuters) - Moderna said on Monday it is collaborating with Immatics to develop cancer vaccines.
Immatics will get $120 million upfront cash as part of the agreement. (Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.43 USD | +2.47% | +6.24% | +18.04% |
May. 15 | Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating | MT |
May. 14 | Immatics' Q1 Loss Narrows. Revenue Rises | MT |
Sept 11 (Reuters) - Moderna said on Monday it is collaborating with Immatics to develop cancer vaccines.
Immatics will get $120 million upfront cash as part of the agreement. (Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
145.4 USD | -1.64% | -12.74% | 56.65B | ||
12.43 USD | +2.47% | +6.24% | 1.25B | ||
1st Jan change | Capi. | |
---|---|---|
+18.04% | 1.25B | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |